Çavdar, Eyyüpİriağaç, Yakup2023-04-202023-04-2020221300-0144https://doi.org/10.55730/1300-0144.5414https://hdl.handle.net/20.500.11776/11101Background/aim: Lymphovascular invasion (LVI) is considered a high-risk factor for recurrence in early-stage breast cancer, hence examination of LVI in pathological samples is an absolute recommendation. We aim to investigate predictive factors of LVI in pre-neoadjuvant chemotherapy (NAC) patients with estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) molecular subtypes of breast cancer. Materials and methods: One hundred and thirty-four patients treated with NAC were included in this study who were ER+/HER2-. The clinical characteristics of the patients, the data obtained from the core needle biopsy before NAC and the LVI status in the pathology that examined after breast surgery were collected. Univariate and multivariate analysis were performed using the logistic regression model. Results: An examination of the association between LVI and clinical-pathological patient characteristics showed that advanced age (>40 years old) (p = 0.021), ductal histology (p = 0.039), and presence of axillary lymph node metastasis (p = 0.005) were predictors of LVI. Independent predictors of LVI in a multivariate logistic model included advanced age (p = 0.037), and the presence of axillary lymph node metastasis prior to NAC (p = 0.006). The median RFS (Recurrence-free survival) time was 22.8 months for all patients. RFS was shorter in patients with LVI (log-rank p = 0.037). Conclusion: Independent predictors of LVI are advanced age and lymph node positivity at the time of diagnosis. Our study is the first study that evaluates pre-NAC predictive factors of LVI in ER+/HER2-breast cancer patients treated with NAC. © TÜBİTAK.en10.55730/1300-0144.5414info:eu-repo/semantics/closedAccessBreast cancerchemotherapylymphovascular invasionpredictivealpha smooth muscle actinCD34 antigencyclophosphamidecytokeratin 7docetaxelepirubicinestrogen receptorKi 67 antigenpaclitaxelprogesterone receptorprotein p63uvomorulinadjuvant therapyadultagedagingArticleaxillary lymph nodebreast cancer recurrencecancer hormone therapydistant metastasisechographyestrogen receptor-positive, HER2-negative breast cancerfemalefluorescence in situ hybridizationfollow uphistologyhumanhuman tissueimmunohistochemistrylymph node biopsylymph node metastasislymph vessel metastasismajor clinical studymultiple cycle treatmentneedle biopsyneoadjuvant chemotherapynuclear magnetic resonance imagingpositron emission tomography-computed tomographyprotein expressionrecurrence free survivalretrospective studythorax radiographytumor volumeArticle52411111117Q3WOS:0008811942000292-s2.0-85136783108114473336326379Q3